RxDoctor Payments Data

Paul Goldstein, MD

Internal Medicine · New York, NYNPI 1659428803

Payments from drug & device makers

$5,445in general payments, 2019–2025

Across 300 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$1K
  • GSK$415
  • Merck$411
  • AstraZeneca$338
  • AbbVie$183
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$5,40099%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,445 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$110,619
Medicare patients
182
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi180$746,455
JulucaDolutegravir/Rilpivirine44$171,360
BiktarvyBictegrav/Emtricit/Tenofov Ala16$107,688
JardianceEmpagliflozin62$83,419
EliquisApixaban62$75,799
MounjaroTirzepatide41$56,339
TivicayDolutegravir Sodium22$48,583
OzempicSemaglutide22$38,116
JanuviaSitagliptin Phosphate25$36,974
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$31,453
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,930
MyrbetriqMirabegron18$11,653
Repatha SureclickEvolocumab14$9,025
XareltoRivaroxaban11$8,783
AmbienZolpidem Tartrate12$7,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Juluca, Tivicay$1,321$966,399246 claims
GileadBiktarvy$1,364$107,68816 claims
PfizerEliquis$173$75,79962 claims
Lilly USA, LLCMounjaro$106$56,33941 claims
Novo NordiskOzempic$43$38,11622 claims
MerckJanuvia$411$36,97425 claims
GSKTrelegy Ellipta$415$11,93019 claims
Astellas Pharma US IncMyrbetriq$42$11,65318 claims
Johnson & JohnsonXarelto$124$8,78311 claims
AbbVieSynthroid$183$1,11416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →